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Abstract
A set of bivalent mannose 6-phosphonate “molecular rulers” has been synthesized to examine ligand
binding to the M6P/IGF2R. The set is estimated to span a P-P distance range of 16–26 Å (MMFF
energy minimization on the hydrated phosphonates). Key synthetic transformations include sugar
triflate displacement for phosphonate installation and Grubbs I cross-metathesis to achieve bivalency.
Relative binding affinities were tested by radioligand displacement assays versus PMP-BSA
(pentamannose phosphate-bovine serum albumin). These compounds exhibit slightly higher binding
affinities for the receptor (IC50’s = 3.7–5 μM) than the parent, monomeric mannose 6-phosphonate
ligand and M6P itself (IC50 = 11.5 ± 2.5 μM). These results suggest that the use of an α-configured
anomeric alkane tether is acceptable, as no significant thermodynamic penalty is apparently paid
with this design. On the other hand, the modest gains in binding affinity observed suggest that this
ligand set has not yet found true bivalent interaction with the M6P/IGF2R (i.e. binding to two distinct
M6P-binding pockets).
The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) is a type I
transmembrane glycoprotein that cycles through the Golgi, endosomes, and the plasma
membrane to carry out its role in the transport of lysosomal enzymes to their cellular
destination.1 The receptor also functions in the binding, uptake, and degradation of the mitogen,
insulin-like growth factor II (IGF-II) and facilitates activation of the growth inhibitor,
transforming growth factor-β. The ability of the M6P/IGF2R to inhibit cell proliferation, or
stimulate apoptosis, by these mechanisms has implicated the receptor as a tumor suppressor.
The IGF-II binding activity of the M6P/IGF2R is mainly responsible for its growth suppressor
function. Many cancers become growth factor-independent by high-level expression of IGF-
II, which not only binds to the M6P/IGF2R, but also to the IGF1R. The high affinity interaction
of IGF-II with the IGF1R leads to activation of IGF1R signaling pathways that promote cell
division and survival.2
§Note: These authors contributed equally to this work.
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The extracellular portion of the M6P/IGF2R contains 15 homologous repeat domains of ~147
amino acid residues each. There are two M6P binding sites located in domains 3 and 9, and
there is one IGF-II binding site in domain 11.3 Binding of high-affinity, M6P-based ligands
and rapid internalization of extracellular ligands, such as IGF-II, are aided by the M6P/IGF2R’s
ability to dimerize.4,5 York et al. demonstrated that β-glucuronidase (hGUS), a homotetrameric
lysosomal enzyme bearing multiple M6P moieties, stabilized the receptor’s dimeric structure
by cross-bridging the M6P binding sites on two adjacent subunits.5 These data support a
dimeric model for binding of bivalent M6P-based ligands by the M6P/IGF2R (Figure 1).
Importantly, they also observed that hGUS binding increased the rate of internalization of the
receptor and consequently stimulated the degradation of any passenger ligands, including IGF-
II, by 3- to 4-fold. The long-term goal of the present work is to exploit this unique property of
bivalent M6P ligands as a potential strategy for therapeutic intervention in IGF-II-dependent
cancer.
Multivalent interactions between receptors and their ligands,6 which are common in biology,
involve a multistep mechanism in which most of the entropic cost is paid by the initial binding
event and subsequent contacts contribute a favorable enthalpy without further sacrifice of
rotational and translational entropy.7 The resultant high binding affinity in these interactions
is due to a reduced rate of ligand-receptor dissociation. This type of interaction occurs in
carbohydrate binding to lectins and is particularly important in the binding of M6P-bearing
oligosaccharides by P-type lectins such as the M6P/IGF2R.
Tong et al. demonstrated that there are two M6P binding sites per monomeric unit of the M6P/
IGF2R.8 Some native glycoprotein ligands and model compounds (e.g. PMP-BSA) display up
to 100- to 1000-fold lower dissociation constants, i.e., higher affinities, than ligands bearing a
single phosphorylated mannoside. Given that two M6P-binding pockets are available per
receptor in the monomeric binding model and four per receptor in the dimeric model, bi- or
multivalency may account for this effect. This could result from simultaneous contact with two
M6P groups on two distinct oligosaccharides. Alternatively, the pioneering work of Varki and
Kornfeld suggested that such high affinity bivalent binding might also be achieved with a single
N-linked oligosaccharide phosphorylated on the two ultimate mannose residues, at the first
and third antennae (Figure 2).9 This high affinity could arise either from intramolecular contact
between a single receptor molecule and the two phosphate groups on the ligand or by
intermolecular cooperation between two subunits within a dimeric receptor structure, as
depicted in Figure 1.
Later work by the Hindsgaul group demonstrated that the linkage between the ultimate Man
and penultimate Man on the phosphorylated branch is important, as an α-1,2-glycosidic linkage
results in a higher binding affinity to the receptor than an α-1,3-linkage (Figure 2).10 A series
of synthetic multivalent ligands for the M6P/IGF2R was prepared by Bock and coworkers,
using a glycopeptide design.11 The best of these compounds bore two mannose disaccharides
capped with phosphate connected by a core peptide of 3 to 5 amino acids. A tripeptide version
of this compound bound the M6P/IGF2R with high affinity, which led to the hypothesis of a
bivalent M6P-based mechanism.5, 11 However, upon closer inspection, it appears that the
exceptional binding affinity of this compound was attributable to an anthranoyl group present
on the lysine ε-amino group within the core peptide (Figure 3). This modification increased
the affinity by ~200-fold relative to the same compound with an unmodified peptide,11
presumably through interaction with a hydrophobic patch on the receptor proximal to the M6P
binding site. Considering that the high affinity of this compound did not arise from a bivalent
M6P-based binding mechanism, it is not surprising that York et al. found that the compound
failed to stabilize the receptor’s dimeric structure or to stimulate its rapid internalization.5 In
summary, there is currently no evidence in the literature of a small synthetic compound capable
of bivalent binding to the M6P/IGF2R by a M6P-based mechanism.
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Thus, the goal of this work is to develop high affinity bivalent M6P-based ligands that
accelerate disposal of IGF-II as a passenger ligand directly in tumors, by cross-bridging the
M6P/IGF2R thereby enhancing its ability to internalize IGF-II. In our previous work, we
discovered that the phosphonate is an excellent surrogate for phosphate to promote equivalent
interaction with the M6P binding domains of the M6P/IGF2R12,13 The phosphonate has the
advantage of resistance to hydrolysis with the potential for improved pharmacokinetics and
efficacy in vivo. In light of the aforementioned studies, we sought to improve affinity by
building bivalency into such ligands.
We have recently demonstrated proof of principle for a Ru-mediated cross-metathesis (CM)
route to joining two M6P surrogates, of both the malonate and phosphonate varieties with a
hydrocarbon tether.12 Herein, we describe the exploitation of this methodology to synthesize
a series of bis-M6P-phosphonates, with incrementally increasing tether lengths as a sort of
“molecular ruler” set to probe for such a bivalent interaction with the receptor. To
systematically increase tether length in two carbon increments, the initial mannosidation
reaction was performed with a series of terminally unsaturated alcohols bearing 4–7 carbons
[from 3-buten-1-ol through 6-hepten-1-ol (Scheme 1).
Initial studies pointed to the need for a modified glycosylation protocol. The previous work
employed HCl gas-mediated glycosylation for allyl alcohol itself, but this approach gave low
yields, in the present work, when applied to longer chain alcohols. Instead, it was found that
TMSOTf-mediated, Vorbrüggen-type glycosylation, using an α-mannosyl acetate glycosyl
donor was quite an efficient reaction. Alkene cross metathesis14 and triflate displacement15
then followed as the key steps, as before, in constructing these compounds. Following a final
alkene hydrogenation/global debenzylation step, the free tethered sugar phosphonates were
obtained. Pleasingly, even with the longest hydrocarbon tether lengths studied here, no
solubility issues were encountered in preparing stock solutions up to 200 mM in a HEPES-
saline buffer, pH 7.4.
Relative binding affinities to M6P/IGF2R were determined by displacement assay using
radiolabeled PMP-BSA as the tracer in the presence of increasing concentrations of each of
the synthetic ligands (Table 1). All the compounds in this new series showed IC50 values in
the micromolar range with ~2-fold increase in RBA compared to M6P alone. This small
increase in RBA likely results from the availability of 2 moles of M6P per mole of ligand
providing a 2-fold increase in the effective competitor concentration, as opposed to any effect
of tether length. Thus, we conclude that these synthetic compounds are binding the M6P/IGF2R
in a monovalent manner. Moreover, these results imply that the two M6-phosphonate moieties
are binding essentially independently, and with no apparent thermodynamic or conformational
penalty paid for the linker (possible issues include: position of attachment, hydrophobicity,
trajectory, etc.)
Dahms and coworkers performed very preliminary modeling studies of the whole receptor,
based on the crystal structure of domains 1–3 using topographical information based on the
amino acid sequence of each domain.16 Using this approach, they estimated the intramolecular
distance of closest approach between the domain 3 and domain 9 M6P binding sites to be ~45
Å. In contrast, they estimated the interphosphate distance between the M6P caps of a bis-
phosphorylated oligosaccharide to be ~30 Å. For comparison, we conducted modeling studies
of our bis-phosphonate ligands to determine if they could span these distances. Using Spartan
04, we built the model structures of the four compounds and added a cluster of six waters
around each phosphonate. In clustering these waters, water-proton/phosphonate oxygen
distances were set at 2.5 Å (hydrogen bonding distance). From energy minimization by
molecular mechanics methods (Spartan 04) using the Merck Molecular Force Field (MMFF),
17 one obtains an estimate of the distance between the two phosphorus atoms in each synthetic
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bis-phosphonate (Table 1). The longest ligand could have a maximum span of ~26 Å (Figure
4). Based on these estimates, our compounds may still be too short to bind in a bivalent manner,
regardless of which receptor binding model is correct.
In addition to the importance of tether length, the structure of the tether is critical to
development of a high-affinity bivalent ligand. The adventitious binding properties of the Bock
compound suggest that additional binding energy may be achieved by adjusting
hydrophobicity, charge and/or π-surface of the tether.11 Moreover, the success enjoyed by the
groups of Bock and Hindsgaul, respectively, in attaining 2–3 orders of magnitude improved
receptor binding over M6P, suggests that peptide- or carbohydrate-based linkers may be
advantageous. Both such tethers present H-bond donor/acceptor functionality across the M6P-
M6P span. They also confer more rigidity than a simply sp3-hybridized alkane tether. Thus,
each peptide bond really represents a degree of pseudo-unsaturation (planarity) with an
expected bias toward a transoid amide geometry.
In conclusion, this study introduces the design and successful synthesis of the first array of bis-
M6-phosphonate-presenting “molecular rulers” to measure distances between M6P-binding
pockets at MPR’s, and to distinguish between intramolecular and intermolecular modes of
bivalent binding. Although the highest M6P/IGF2R binding affinity seen in the ligand set is
in the micromolar range [IC50 ~ 4 μM], no solubility problems or tether penalty issues were
encountered. Moreover, the replacement of the M6P ester with a hydrolytically stable
phosphonate surrogate persists as an effective design, across the entire set, and reinforces the
notion that phosphatase resistance can be incorporated into such small molecule probes.
Completion of these studies will require that we find a high-affinity ligand that stabilizes the
dimeric structure of the receptor and thereby promotes rapid internalization of IGF-II in a
cellular model. Ultimately, a new compound that exhibits all these properties would potentially
be testable in an animal model for inhibition for IGF-II-driven tumor growth.
In closing, we note that the combination of cross-metathesis to build the bivalent sugar scaffold,
and bis-triflate displacement to introduce the phosphate-surrogate late in the synthesis, is a
powerful approach. This strategy is likely amenable to the introduction of other phosphate-
mimicking functionality in the endgame, and more generally, is likely extendible to the study
of other multivalent ligand-protein interactions.
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Figure 1.
M6P ligand binding to the M6P/IGF2R: The alternative “hook and ladder” models: A. One
monomeric unit of the M6P/IGF2R consisting of the 15 extracellular repeating domains,
transmembrane domain, and a short cytoplasmic tail. The M6P/IGF2R is depicted as forming
a hook-like structure when a ligand bearing two M6P groups binds to domains 3 and 9 (lighter
shaded ovals). B. Two monomeric units of the M6P/IGF2R are connected through binding by
ligands that interact with either domain 3 or 9 of two individual monomeric units to form a
dimeric ladder-like structure.
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Figure 2.
Hindsgaul’s model biantennary ligands
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Figure 3.
Bock’s tripeptide bis-M6P-bearing ligands
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Figure 4.
One of several low energy chain-extended conformers found by an MMFF molecular
mechanics minimization on the hydrated 12-carbon-spaced ligand. See Table 1 for the P,P-
distance range found for the set of such conformers.
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Scheme 1.
Reagents and conditions: (a) NaH, BnBr, DMF, 0 °C to rt (90%); (b) AcOH, Ac2O, H2SO4, 0
°C (82%); (c) 2 TMSOTf, 3-buten-1-ol, rt (86%); 3 TMSOTf, 4-penten-1-ol, rt (70%); 4
TMSOTf, 5-hexen-1-ol, rt (63%); 5 TMSOTf, 6-hepten-1-ol, rt (62%); (d) Grubbs I catalyst,
DCM, 40 °C: 6 (81%); 7 (78%); 8 (69%); 9 (70%); (e) Sodium methoxide, methanol, rt
(quantitative); (f) 2,6-di-tert-butyl-4-methylpyridine, Tf2O, DCM, −40 °C; (g) n-BuLi,
dibenzyl methyl-phosphonate, THF, −78 °C (two step yields): 14 (67%); 15 (59%); 16
(33%); 17 (18%); (h) H2 (balloon pressure), Pd/C, rt; (i) NH4HCO3 (50 mM) aqueous solution,
rt (two step yields): 18 (66%); 19 (71%); 20 (68%); 21 (62%).
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Table 1
Relative M6P/IGF2R binding affinities
Ligand IC50(n) μMa RBAb Mr Lgthc
M6P 11.5 ± 2.51 (4) 1.0 340 NA
G6P >10 (4) NA 282 NA
18 (6C) 4.76 ± 2.50 (4) 2.63 ± 0.74 666 16.2–19.5 Å
19 (8C) 5.03 ± 1.34 (4) 2.39 ± 0.83 694 19.2–20.9 Å
20 (10C) 4.44 ± 1.40 (4) 2.65 ± 0.52 722 19.6–22.7 Å
21 (12C) 3.70 ± 0.56 (4) 3.02 ± 0.41 750 24.6–26.0 Å
a
IC50’s for competitive displacement of radiolabeled PMP-BSA from the receptor (n = no. of trials, see SI for details); G6P = glucose 6-phosphate
b
RBA = relative binding affinity, normalized to free M6P;
c
Length = P-P distance, as estimated by molecular mechanics minimization (MMFF). For each compound, minimizations were run from five different,
chain-extended starting conformers. The P-P distances given represent the ranges seen for the set of low energy, chain-extended conformers found.
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